



Veritas In Silico and Takeda Enter Into Collaborative Research and License Agreement for mRNA-Targeted Small Molecule Drugs

Tokyo, Japan, June 23, 2023 - Veritas In Silico Inc. (“VIS”) announced today that it has entered into a collaborative research and license agreement with Takeda with the goal to discover and develop innovative small molecule medicines against multiple mRNAs of genetically-defined diseases.

The collaboration will leverage VIS’s proprietary mRNA-targeted drug discovery platform, ibVIS®, which consists of computational target identification of any given mRNA, robust and quantitative high throughput screening, and various drug discovery technologies fully optimized for mRNA targets. Takeda will have all the rights to develop, manufacture and market the products worldwide resulting from the collaboration.

Under the terms of the agreement, VIS will receive an upfront payment and research payment and will be eligible to receive preclinical, clinical and commercial milestone payments if all milestones are achieved during the term of the agreement. Additionally, VIS is entitled to royalties on the net sales of any commercial product resulting from the collaboration.

“We are very excited to partner with Takeda on this drug discovery collaboration”, said Dr. Shingo Nakamura, Representative Director, Founder and CEO, VIS. “Fully leveraging our mRNA-targeted drug discovery platform, we will collaborate with Takeda to discover innovative small molecule medicines for diseases where promising treatments are long-awaited.”

About Veritas In Silico Inc.

VIS aims to realize a society where every patient can look forward to a brighter future through next-generation small molecule drug discovery targeting mRNA. VIS, as a pathfinder in mRNA-targeted drug discovery, has established a fully integrated drug discovery platform, ibVIS®, including lots of in-house software with rule-based AI, and has been conducting drug discovery research in collaboration with pharmaceutical companies since 2018 to create mRNA-targeted small molecule medicines for therapeutic areas such as oncology, neurology and infectious diseases.

For more information on VIS, visit <https://www.veritasinsilico.com/en/>.

Press Contact

Veritas In Silico Inc.
contact@veritasinsilico.com